Aterian
ATER

$2.97

2.77%

Market Cap: 25.5M

About: Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operated brands including Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.

Employees: 114

Consumer Discretionary Electric Housewares & Fans

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

987% more call options, than puts

Call options by funds: $598K | Put options by funds: $55K

0.21% less ownership

Funds ownership: 7.02% [Q4 2023] → 6.81% (-0.21%) [Q1 2024]

37% less capital invested

Capital invested by funds: $2.21M [Q4 2023] → $1.38M (-$826K) [Q1 2024]

40% less funds holding

Funds holding: 43 [Q4 2023] → 26 (-17) [Q1 2024]

89% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 19

91% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 22

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ATER.

See Analyst Rankings

Financial journalist opinion

Aterian: Cheap, But Speculative Turnaround Play - Upgrade To Buy

After the close of Wednesday's regular session, e-commerce brand consolidator Aterian raised Q2 expectations for botth the top- and bottom line. Following years of revenue declines and material cash burn, the company is finally showing signs of life. At the high-end of the increased range, the company would break-even on an Adjusted EBITDA basis for the first time since Q3/2021.

Aterian: Cheap, But Speculative Turnaround Play - Upgrade To Buy

Aterian Announces Leadership Changes & Improved Second Quarter 2024 Net Revenue and Adjusted EBITDA Ranges

Arturo Rodriguez Appointed CEO Josh Feldman Appointed CFO Second Quarter 2024 Net Revenue Range Improved to Between $23 Million to $26 Million Second Quarter 2024 Adjusted EBITDA Range Improved to Between a Loss of ($1.0) Million to $0.0 Million NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Aterian, Inc. (Nasdaq: ATER) (“Aterian” or the “Company”) today announced the appointment of Arturo (Arty) Rodriguez as Chief Executive Officer (previously the Company's Co-CEO and CFO) and Josh Feldman as Chief Financial Officer (previously the Company's SVP of Finance) and that Joe Risico has resigned as Co-CEO and from the Board of Directors and will consult the Company over a three month transition period. “On behalf of our Board of Directors, we express our deep gratitude for Joe's passion, innovative ideas, and relentless work ethic.

Aterian Announces Leadership Changes & Improved Second Quarter 2024 Net Revenue and Adjusted EBITDA Ranges

Aterian Investment Partners Acquires Contract Pharmaceuticals Limited

NEW YORK & MIAMI--(BUSINESS WIRE)--Aterian Investment Partners (“Aterian”), a private investment firm, is pleased to announce that one of its affiliates has closed its acquisition of Contract Pharmaceuticals Limited Canada (“CPL” or the “Company”), a leading North American contract development and manufacturing organization (CDMO) of non-sterile liquid and semi-solid dosage forms. Based in Mississauga, Ontario, Canada, CPL is an industry leader with longstanding relationships with 15 of the top.

Aterian Investment Partners Acquires Contract Pharmaceuticals Limited

Aterian, Inc. (ATER) Q1 2024 Earnings Call Transcript

Aterian, Inc. (NASDAQ:ATER ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Ilya Grozovsky - Vice President, IR & Corporate Development Joseph Risico - Co-CEO Arturo Rodriguez - Co-CEO & CFO Conference Call Participants Brian Kinstlinger - Alliance Global Partners Marvin Fong - BTIG Operator Thank you for standing by. My name is Alex, and I will be your conference operator today.

Aterian, Inc. (ATER) Q1 2024 Earnings Call Transcript

Aterian Reports First Quarter 2024 Results

First Quarter Net Loss Improved by 80.0% Year Over Year and Adjusted EBITDA Loss Improved by 38.4% Affirms Second Half 2024 Adjusted EBITDA Profitability Target NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Aterian, Inc. (Nasdaq: ATER) (“Aterian” or the “Company”) today announced results for the first quarter ended March 31, 2024. First Quarter Highlights First quarter 2024 net revenue declined 42.0% to $20.2 million, compared to $34.9 million in the first quarter of 2023.

Aterian Reports First Quarter 2024 Results

Aterian Sets Date for First Quarter 2024 Earnings Announcement & Investor Conference Call

NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Aterian, Inc. (Nasdaq: ATER) (“Aterian”) announced today that it plans to report its first quarter 2024 financial results after the market close on Tuesday, May 7, 2024, and plans to host a conference call for investors and interested parties at 5:00 p.m. ET that evening.

Aterian Sets Date for First Quarter 2024 Earnings Announcement & Investor Conference Call

Aterian Announces Improved First Quarter 2024 Net Revenue and Adjusted EBITDA Ranges

First Quarter Net Revenue Range Improved to $20.0 Million to $21.0 Million First Quarter Adjusted EBITDA Loss Range Improved to ($2.4) Million to ($2.9) Million NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Aterian, Inc. (Nasdaq: ATER) (“Aterian” or the “Company”) today announced updates to its previously announced net revenue and Adjusted EBITDA ranges for the first quarter of 2024 ended March 31, 2024. The net revenue and Adjusted EBITDA information is based on preliminary data, which has not been subjected to normal quarter end closing and review procedures.

Aterian Announces Improved First Quarter 2024 Net Revenue and Adjusted EBITDA Ranges

Aterian Investment Partners to Recapitalize CPL, a Leading Pharmaceutical Contract Development and Manufacturing Organization

NEW YORK & MIAMI--(BUSINESS WIRE)--Aterian Investment Partners (“Aterian”), a private investment firm, is pleased to announce that one of its affiliates has entered into an agreement to recapitalize Contract Pharmaceuticals Limited Canada ("CPL" or the “Company”), a leading North American contract development and manufacturing organization (CDMO) of non-sterile liquid and semi-solid dosage forms. CPL, based in Mississauga, Ontario, Canada, is an industry leader with longstanding relationships w.

Aterian Investment Partners to Recapitalize CPL, a Leading Pharmaceutical Contract Development and Manufacturing Organization

Aterian Announces Reverse Stock Split

Expected to Start Trading on a Split-adjusted Basis Beginning March 22, 2024 Expected to Start Trading on a Split-adjusted Basis Beginning March 22, 2024

Aterian Announces Reverse Stock Split

Aterian, Inc. (ATER) Q4 2023 Earnings Call Transcript

Aterian, Inc. (ATER) Q4 2023 Earnings Call Transcript

Aterian, Inc. (ATER) Q4 2023 Earnings Call Transcript

See News Rankings